Luminex Bio-Plex utilizes xMAP technology comprising a magnetic or non-magnetic bead-based flow cytometric platform. The Luminex system creates unique spectral addresses for the microspheres by labeling them as per the different ratios of red and far-red fluorophores. This technology can detect multiple targets in a single immunoassay system by assigning each of them with a unique address through the covalent attachment of these fluorescent antibodies to the beads. Thus, this multiplexed immunoassay system with a microplate format can simultaneously analyze up to 100 different nucleic acids, proteins, or peptides.
By using the Luminex Bio-Plex platform, we can detect and quantitate multiple biomarker proteins in the provided samples to evaluate the safety and efficacy of your therapeutics. Furthermore, Luminex bead-based assays can be used in bioanalytical studies utilizing cell-based assays and biomarkers for cardiac, kidney, inflammation, cancer, apoptosis, toxicity, obesity, and intracellular cell signaling (including phosphoproteins and nucleic acids). High-performance multiplex assay kits available through this platform can be a valuable asset in basic and translational research on various diseases for the simultaneous analysis of multiple proteins, including growth factors and cytokines such as interferons, interleukins, chemokines, and members of the tumor necrosis superfamily.’
Here’s a comprehensive protocol for Luminex Bio-Plex bead based assay –
Generally, a chain is formed comprising the bead—target protein—fluorescent capture antibody—biotinylated target-specific antibody—streptavidin-PE when the samples contain a target of any given biotinylated antibody. Then, we draw a single-file of these Luminex beads into a flow cell to be excited by two lasers. This dual laser flow-based system identifies the signature of each bead and simultaneously detects the presence and intensity of the associated reporter (phycoerythrin). This Luminex Bio-Plex assay helps identify and quantitate targets in the sample as a high-speed digital signal processor manages the fluorescent output.
Luminex immunoassays can multiplex by incubating several pre-coated bead sets with different samples in a microtiter plate. The Luminex Bio-Plex reader identifies the address of each bead and quantitates the present target antigen. Thus, Luminex technology can analyze up to 100 target proteins in as little as 12.5 μL sample per reaction as compared to a single-plex Enzyme-linked Immunoassay (ELISA) that requires 100-200 μL sample per well to detect one target protein.
Moreover, high-performance Luminex multiplex assay kits are available that streamline assay time and costs during the simultaneous analysis of multiple growth factors and cytokines, etc. Also, a more extensive range of analyses is possible as patient specimens and other valuable analytes can be utilized more judiciously, given the lower sample volumes. That said, we must consider antibody cross-reactivity when designing multiplex experiments using Luminex Bio-Plex.
Luminex can facilitate the identification and quantification of multiple biomarker proteins to identify higher-risk patients, determine disease prognosis, or monitor treatment efficacy. A few benefits of Luminex Bioplex assay are listed below –
At NorthEast BioLab, we perform your bioanalytical assays to analyze your tissue and fluid-based biomarkers using state-of-the-art technology, such as the Luminex Bio-Plex platform. We are experts in GLP and GCP biomarker assessments, including method development and validation for novel and identified biomarkers. Luminex Bio-Plex is highly customizable and includes user-friendly software that automatically generates standard curves of known concentrations of all analytes and displays data in graphic or tabular form. Furthermore, the integration of kits, software, calibration, and validation beads, and instrumentation makes Luminex Bio-Plex a reliable high-throughput multiplex assay system.